1 Green D，Hirsh J，Heit J，et al．Low molecular weight heparin：A critical analysis of clinical trials．Pharmacol Rev，1994，46(1)：90． 2 Brace LD，Fareed J．Heparin-induced Platelet aggregation Ⅱ．dose/response relationships for two low molecular weight heparin fractions．Thromb Res，1990，59(1)：1． 3 Aster RH．Heparin-Induced thrombocytopenia and thrombosis．N Eng J Med，1995，332(20)：1374． 4 Kelton JG，Hirsh J．Bleeding associated with antithrombotic therapy．Semin Hematol，1980，17(4)：259． 5 Pifarre R，Babka R，Sullivan HJ，et al．Management of postoperative heparin rebound following cardiopulmonary bypass．J Thorac Cardiovasc Surg，1981，81(3)：378． 6 Henny CHP，Ten Cate H，Ten Cate J·W，et al．A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs．J Lab Clin Med，1985，106(2)：187． 7 Meuleman DG，Hobbelen PML，Dedem GV．et al．A novel antithmmbotie heparinoid (ORGl0172) devoid of bleeding inducing capacity：A survey of its pharmacological properities in experimental animal models．Thromb Res．1982，27(3)：353． 8 Gouault-Heilmann M，Huet Y，Conlant G，et al．Cardiopulmonary bypass with a low molecular weight heparin fraction．Lancet，1983，2(8363)：1374． 9 Blackshear JL，Callgahn WG，Califf RM．Medical approaches to prevention of restenosis after coronary angioplasty．J Am Coll Cardiol．1987，9(4)：834． 10 Currier JW，Pow TK，Hauderschild CC，et al，Low molecular weight heparin (Enoxaparin) reduces restenosis after iliac angioplasty in the hypercholesterolemie rabbit．J Am Coll Cardiol，1991，17(6 Suppl B)：118B． 11 Yilmaz S．Paavonen T，Hayry P．Chronic rejection of rat renal allografts Transplantation，1992，53(4)：823． 12 Wanders A．Akyurek ML，Waltenberger J，et al．Ischemia induced transplant arteriosclerosis in the rat．Arterioscter Thromb Vasc Biol．1995，15(1)：145． 13 Akyurek ML，Wanders A，Aurivillius M，et al．Effects of angiopeptin on transplant arteriosclerosis in the rat Transplant Int，1995，8(2)：103． 14 Libby P，Tanaka H．The Pathogenes of coronary arteriosclerosis (“chronicrejection”) in transplanted hearts．Clin Transplant，1994，8(3 pt 2)：313． 15 Rubin K，Tingstrom A，Hansson GK，Ronnstrand L．et al．Induction of Btype receptors for platelet-derived growth factor ln vascular inflammation：possible implications for development of vascular proliferative lesions．Lancet，1988，1(8599)：1353． 16 Sakuda H，Nakoshima Y，Kuriyama S，et al．Media conditioned by smooth muscle cells cultured ln a variety of hypoxic environments stimulates in vitro angiogenesis．A relationship to transforming growth factor-β l．Am J Pathlo，1992，141(6)：1507． 17 Russell R，Glomset J，Kariya B，et al．A platelet dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro．Proc Nati Acad Sci USA．1974，71(4)：1207． 18 Levent MA，Keiko F，Alkwin W．Et al Inhibition of transplant arteriosclerosis in rat aortic grafts by low molecular weight heparin derivatives．Transplantation，1995．59(11)：1517． 19 FelIstrom BC．Larsson E．Pathogenesis and treatment perspectives of chronic graft rejection (CVR)．Immunol Rev，1993，134：83． 20 Berk BC，Gordon JB，Alexander RW．Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty． J Am Coll Cardiol，1991，17(6 8upplB)：111B．